» Articles » PMID: 10482625

Replication of Aleutian Mink Disease Parvovirus in Vivo is Influenced by Residues in the VP2 Protein

Overview
Journal J Virol
Date 1999 Sep 11
PMID 10482625
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Aleutian mink disease parvovirus (ADV) is the etiological agent of Aleutian disease of mink. Several ADV isolates have been identified which vary in the severity of the disease they elicit. The isolate ADV-Utah replicates to high levels in mink, causing severe Aleutian disease that results in death within 6 to 8 weeks, but does not replicate in Crandell feline kidney (CrFK) cells. In contrast, ADV-G replicates in CrFK cells but does not replicate in mink. The ability of the virus to replicate in vivo is determined by virally encoded determinants contained within a defined region of the VP2 gene (M. E. Bloom, J. M. Fox, B. D. Berry, K. L. Oie, and J. B. Wolfinbarger. Virology 251:288-296, 1998). Within this region, ADV-G and ADV-Utah differ at only five amino acid residues. To determine which of these five amino acid residues comprise the in vivo replication determinant, site-directed mutagenesis was performed to individually convert the amino acid residues of ADV-G to those of ADV-Utah. A virus in which the ADV-G VP2 residue at 534, histidine (H), was converted to an aspartic acid (D) of ADV-Utah replicated in CrFK cells as efficiently as ADV-G. H534D also replicated in mink, causing transient viremia at 30 days postinfection and a strong antibody response. Animals infected with this virus developed diffuse hepatocellular microvesicular steatosis, an abnormal accumulation of intracellular fat, but did not develop classical Aleutian disease. Thus, the substitution of an aspartic acid at residue 534 for a histidine allowed replication of ADV-G in mink, but the ability to replicate was not sufficient to cause classical Aleutian disease.

Citing Articles

Aleutian mink disease: Spatio-temporal variation of prevalence and influence on the feral American mink.

Zalewski A, Virtanen J, Brzezinski M, Kolodziej-Sobocinska M, Jankow W, Sironen T Transbound Emerg Dis. 2020; 68(4):2556-2570.

PMID: 33197283 PMC: 8359164. DOI: 10.1111/tbed.13928.


Genetic characterization of the complete genome of an Aleutian mink disease virus isolated in north China.

Xi J, Wang J, Yu Y, Zhang X, Mao Y, Hou Q Virus Genes. 2016; 52(4):463-73.

PMID: 27007772 DOI: 10.1007/s11262-016-1320-3.


Role of capsid proteins in parvoviruses infection.

Tu M, Liu F, Chen S, Wang M, Cheng A Virol J. 2015; 12:114.

PMID: 26239432 PMC: 4524367. DOI: 10.1186/s12985-015-0344-y.


Phylogenetic analysis of the VP2 gene of Aleutian mink disease parvoviruses isolated from 2009 to 2011 in China.

Sang Y, Ma J, Hou Z, Zhang Y Virus Genes. 2012; 45(1):31-7.

PMID: 22415542 DOI: 10.1007/s11262-012-0734-9.


Virulent variants emerging in mice infected with the apathogenic prototype strain of the parvovirus minute virus of mice exhibit a capsid with low avidity for a primary receptor.

Rubio M, Lopez-Bueno A, Almendral J J Virol. 2005; 79(17):11280-90.

PMID: 16103180 PMC: 1193584. DOI: 10.1128/JVI.79.17.11280-11290.2005.


References
1.
Hahn E, Ramos L, Kenyon A . Expression of Aleutian mink disease antigen in cell culture. Infect Immun. 1977; 15(1):204-11. PMC: 421350. DOI: 10.1128/iai.15.1.204-211.1977. View

2.
Bloom M, Fox J, Berry B, Oie K, Wolfinbarger J . Construction of pathogenic molecular clones of Aleutian mink disease parvovirus that replicate both in vivo and in vitro. Virology. 1998; 251(2):288-96. DOI: 10.1006/viro.1998.9426. View

3.
An S, DePauli F, Wright P, Ingram D . Characteristics of inapparent Aleutian disease virus infection in mink. Res Vet Sci. 1978; 24(2):200-4. View

4.
Bloom M, Race R, Wolfinbarger J . Characterization of Aleutian disease virus as a parvovirus. J Virol. 1980; 35(3):836-43. PMC: 288877. DOI: 10.1128/JVI.35.3.836-843.1980. View

5.
Davis L, Cole L, Lockwood S, Kornfeld M . Experimental influenza B virus toxicity in mice. A possible model for Reye's syndrome. Lab Invest. 1983; 48(2):140-7. View